PRLD — Prelude Therapeutics Incorporated Share News
0.000.00%
Last trade - 00:00- $236.22m
- $84.47m
- $12.14m
Brief: Prelude Therapeutics Q1 EPS USD -0.42
Prelude Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview
Prelude Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Prelude Therapeutics FY Operating Expenses USD 146.714 Million
Prelude Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview
Brief: Prelude Therapeutics Names Bryant Lim As Permanent CFO
Brief: Prelude Therapeutics Presents Preliminary Results Of Phase 1 Dose-Escalation Study Of PRT2527 As Monotherapy And In Combination With Zanubrutinib
Brief: Prelude Therapeutics Q3 EPS USD -0.43
Prelude Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview
Brief: Prelude Therapeutics Says PRT3789 Generally Well-Tolerated With No Dose-Limiting Toxicities
Prelude Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Prelude Therapeutics Q2 Net Income USD -34.74 Million
Prelude Therapeutics Inc expected to post a loss of 42 cents a share - Earnings Preview
Brief: Prelude Therapeutics Announces Collaboration With Merck For PRT3789 In Combination With Keytruda In SMARCA4-Mutated Cancers
Brief: Prelude Therapeutics Inc Files For Mixed Shelf Of Up To $400 Million – SEC Filing
Prelude Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Prelude Therapeutics Q1 EPS USD -0.42 Vs. IBES Estimate USD -0.48
Prelude Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: Prelude Therapeutics Inc CFO Laurent Chardonnet Resigns